Omega-3 Supplementation on Serum Fetuin-A Levels
Coronary Artery Disease
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring Fetuin-A, Omega-3 fatty acid, Coronary artery disease, Nutrient intake
Eligibility Criteria
Inclusion Criteria: Male volunteer patients aged 35-75 years Patients with newly diagnosed with coronary artery disease by conventional coronary angiography Exclusion Criteria: Individuals who have dieted in the last six months Use of omega-3 fatty acid and/or vitamin/mineral supplements or statin group drugs BMI <18.5 and ≥40 kg/m2 Fasting blood glucose ≥ 126 mg/dL Presence of systemic diseases such as Type 1 and Type 2 diabetes, kidney diseases, liver diseases, cancer or neurological diseases Active athletes and/or those who exercise regularly
Sites / Locations
- Gazi University Training and Research Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Omega-3 Group
Control Group
While 1.560 mg/day omega-3 FA supplementation was given to the patients in the omega-3 group for eight weeks, but not in the control group.
While 1.560 mg/day omega-3 FA supplementation was given to the patients in the omega-3 group for eight weeks, but not in the control group.